Compare Main Street Capital Corporation (MAIN) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs McKesson Corporation — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.09B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 20.9× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and McKesson Corporation for 74 Days on average.
| MAIN | MCK | |
|---|---|---|
Market Cap | $5.09B | $106.14B |
Volume | 524,060 | 794,405 |
Sector | Financials | Health |
52-Week High | $64.60 | $995.69 |
52-Week Low | $49.63 | $725.17 |
Typical Hold Time | 88 Days | 74 Days |
Enterprise Value | $7.54B | $112.67B |
Dividend Yield | 5.84% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $592 million and net income of $493 million for 2025, with a net income margin of 83.36%. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. Analyst consensus is a Hold with a $58.33 price target, indicating modest upside potential.
Outlook: MAIN offers a stable dividend history and strong profitability, but faces headwinds from softening revenue projections for 2026 and negative operating cash flow. Risks include earnings volatility and high valuation multiples. The stock presents a cautious opportunity for income-focused investors, balanced by near-term fundamental pressures.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
